Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

This study has been completed.

Study NCT00006010 Information provided by National Cancer Institute (NCI)

First Received: July 5, 2000 Last Updated: May 13, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)

Publications:

Alberts SR, Reid JM, Morlan BW, Farr GH, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and Docetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2011 May 6; [Epub ahead of print]

Kim GP, Alberts SR, Tschetter LK, et al.: Gemcitabine and docetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma (HCC), a North Central Cancer Treatment Group (NCCTG) phase II trial. [Abstract] J Clin Oncol 22 (Suppl 14): A-4270, 380s, 2004.